share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K：重大事件
美股SEC公告 ·  2024/05/29 19:38

Moomoo AI 已提取核心信息

bluebird bio, Inc. has announced a significant change in its executive team with the departure of Christopher Krawtschuk as Chief Financial Officer and principal accounting officer, effective June 10, 2024. The company clarified that Krawtschuk's departure is not due to any disagreements on accounting policies or business strategy. Concurrently, the Board of Directors has appointed O. James Sterling as the new Chief Financial Officer, with his role also commencing on June 10, 2024. Sterling brings experience from his previous role as CFO of Renalytix plc and has held positions at Renwick Capital LLC and investment banks Brock Capital Group LLC and Aleutian Capital Group. His appointment comes with a comprehensive compensation package, including a $500,000 annual salary, a $100,000 sign-on bonus, a 45% target annual bonus, and an initial equity grant. The company has detailed the terms of Sterling's employment and severance provisions, as well as the severance arrangements for Krawtschuk, in line with his existing employment agreement.
bluebird bio, Inc. has announced a significant change in its executive team with the departure of Christopher Krawtschuk as Chief Financial Officer and principal accounting officer, effective June 10, 2024. The company clarified that Krawtschuk's departure is not due to any disagreements on accounting policies or business strategy. Concurrently, the Board of Directors has appointed O. James Sterling as the new Chief Financial Officer, with his role also commencing on June 10, 2024. Sterling brings experience from his previous role as CFO of Renalytix plc and has held positions at Renwick Capital LLC and investment banks Brock Capital Group LLC and Aleutian Capital Group. His appointment comes with a comprehensive compensation package, including a $500,000 annual salary, a $100,000 sign-on bonus, a 45% target annual bonus, and an initial equity grant. The company has detailed the terms of Sterling's employment and severance provisions, as well as the severance arrangements for Krawtschuk, in line with his existing employment agreement.
蓝鸟生物公司宣布，随着克里斯托弗·克劳茨丘克辞去首席财务官兼首席会计官的职务，其执行团队将进行重大变动，该职位将于2024年6月10日生效。该公司澄清说，Krawtschuk的离职不是由于会计政策或业务战略上的任何分歧造成的。同时，董事会已任命 O. James Sterling 为新任首席财务官，其职位也将于 2024 年 6 月 10 日开始。斯特林拥有之前担任Renalytix plc首席财务官的经验，曾在伦威克资本有限责任公司和投资银行布罗克资本集团有限责任公司和阿留申资本集团任职。他的任命附带了全面的薪酬待遇，包括50万美元的年薪、100,000美元的签约奖金、45％的目标年度奖金和初始股权补助。该公司根据斯特林现有的雇佣协议，详细介绍了斯特林的雇佣和遣散费条款以及对Krawtschuk的遣散费安排。
蓝鸟生物公司宣布，随着克里斯托弗·克劳茨丘克辞去首席财务官兼首席会计官的职务，其执行团队将进行重大变动，该职位将于2024年6月10日生效。该公司澄清说，Krawtschuk的离职不是由于会计政策或业务战略上的任何分歧造成的。同时，董事会已任命 O. James Sterling 为新任首席财务官，其职位也将于 2024 年 6 月 10 日开始。斯特林拥有之前担任Renalytix plc首席财务官的经验，曾在伦威克资本有限责任公司和投资银行布罗克资本集团有限责任公司和阿留申资本集团任职。他的任命附带了全面的薪酬待遇，包括50万美元的年薪、100,000美元的签约奖金、45％的目标年度奖金和初始股权补助。该公司根据斯特林现有的雇佣协议，详细介绍了斯特林的雇佣和遣散费条款以及对Krawtschuk的遣散费安排。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！